Biograil ApS

https://www.biograil.com

Biograil is a Danish start-up using injection molding to manufacture a device contained in a standard size capsule able to deliver active substances into the gastrointestinal wall. The Biograil device avoids mechanical moving components and makes use of the body’s own peristaltic forces to facilitate the delivery of the biologic efficiently into the gastrointestinal wall. The team behind Biograil is a combination of seasoned entrepreneurs with long experience in creating successful biotech companies as well as R&D executives behind the world’s first injection molded oral tablet to be approved by the FDA. *

	Start	2019-01-01 established (s-off)
	Industry	oral drug delivery technology for biologics
	Industry 2	drug delivery technology (drug formulation technology)
	Person	Lindhardt, Karsten (Biograil 202001 CEO before Egalet + Novo Nordisk + Ferring + Prosidion + Curalogic)

	Region	Denmark_oo
	Country	Denmark
	Street	2 Baldersbuen
	City	2640 Hedehusene
	Tel	+45-21-663941
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: High-Tech Gründerfonds Management GmbH. (1/15/20). "Press Release: Biograil Secures Seed Funding for Oral Delivery Device with Potential to Transform Market for Injectables".

		Record changed: 2024-02-12

Picture Berlin Partner BIO 2024 International Convention San Diego 650x200px

More documents for Biograil ApS

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)